Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–231 of 231
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells
Sarthy, A. V., Morgan-Lappe, S. E., Zakula, D., Vernetti, L., Schurdak, M., Packer, J. C. L., Anderson, M. G., Shirasawa, S., Sasazuki, T., & Fesik, S. W. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0560 · Cited by 78
Self-citationUS National Cancer Institute's new Ras project targets an old foe
Thompson, H. (2013) · Nature Medicine · doi:10.1038/nm0813-949 · Cited by 74
Targeting eNOS in Pancreatic Cancer
Lampson, B. L., Kendall, S. D., Ancrile, B. B., Morrison, M. M., Shealy, M. J., Barrientos, K. S., Crowe, M. S., Kashatus, D. F., White, R. R., Gurley, S. B., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0057 · Cited by 74
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Karlsson, C., Andersson, K. M. E., Liu, M., Sjogren, A.-K. M., Swolin, B., Young, S. G., & Bergo, M. O. (2007) · Blood · doi:10.1182/blood-2006-05-024752 · Cited by 72
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice
Haklai, R., Elad‐Sfadia, G., Egozi, Y., & Kloog, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0451-6 · Cited by 69
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J., Jacks, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0096 · Cited by 68
Phosphorylation of RalB Is Important for Bladder Cancer Cell Growth and Metastasis
Wang, H., Owens, C., Chandra, N., Conaway, M. R., Brautigan, D. L., & Theodorescu, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0952 · Cited by 67
The Ras AntagonistS-Farnesylthiosalicylic Acid Induces Inhibition of MAPK Activation
Gana‐Weisz, M., Haklai, R., Marciano, D., Egozi, Y., Ben‐Baruch, G., & Kloog, Y. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7582 · Cited by 66
Vigil, D., Martin, T. D., Williams, F., Yeh, J. J., Campbell, S. L., & Der, C. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116756 · Cited by 65
Self-citationSmall-Molecule Inhibitors of the Rce1p CaaX Protease
Manandhar, S. P., Hildebrandt, E. R., & Schmidt, W. K. (2007) · SLAS Discovery · doi:10.1177/1087057107307226 · Cited by 63
The prenyl-binding protein PrBP/δ: A chaperone participating in intracellular trafficking
Zhang, H., Constantine, R., Frederick, J. M., & Baehr, W. (2012) · Vision Research · doi:10.1016/j.visres.2012.08.013 · Cited by 62
Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth
Barceló, C., Paco, N., Morell, M., Alvarez-Moya, B., Bota-Rabassedas, N., Jaumot, M., Vilardell, F., Capella, G., & Agell, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1750 · Cited by 61
Immunotherapy at Large: The road to personalized cancer vaccines
Vonderheide, R. H., & Nathanson, K. L. (2013) · Nature Medicine · doi:10.1038/nm.3317 · Cited by 54
Court, H., Amoyel, M., Hackman, M., Lee, K. E., Xu, R., Miller, G., Bar-Sagi, D., Bach, E. A., Bergö, M. O., & Philips, M. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65764 · Cited by 54
McMahon, L. P., Yue, W., Santen, R. J., & Lawrence, J. C. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0305 · Cited by 54
Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
Muvaffak, A., Pan, Q., Yan, H., Fernandez, R., Lim, J., Dolinski, B., Nguyen, T. T., Strack, P., Wu, S., Chung, R., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0642 · Cited by 49
A High-Throughput Soft Agar Assay for Identification of Anticancer Compound
Anderson, S. N., Towne, D. L., Burns, D. J., & Warrior, U. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107306130 · Cited by 47
Chen, X., Makarewicz, J. M., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2014) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 46
Stress eating and tuning out: Cancer cells re-wire metabolism to counter stress
Stine, Z. E., & Dang, C. V. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.844093 · Cited by 46
The new sulindac derivative IND 12 reverses Ras-induced cell transformation.
Karaguni, I., Herter, P., Debruyne, P. R., Chtarbova, S., Kasprzynski, A., Herbrand, U., Ahmadian, M.-R., Glüsenkamp, K., Winde, G., Mareel, M. M. K., et al. (2002) · PubMed · Cited by 45
González-Pérez, V., Reiner, D. J., Alan, J. K., Mitchell, C., Edwards, L. J., Khazak, V., Der, C. J., & Cox, A. D. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-2 · Cited by 42
Self-citationDesign, Synthesis and Biological Evaluation of Sugar‐Derived Ras Inhibitors
Peri, F., Airoldi, C., Colombo, S., Martegani, E., van Neuren, A. S., Stein, M., Marinzi, C., & Nicotra, F. (2005) · ChemBioChem · doi:10.1002/cbic.200400420 · Cited by 41
Martin, T. D., Mitin, N., Cox, A. D., Yeh, J. J., & Der, C. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.344986 · Cited by 38
Self-citationMajmudar, J. D., Hodges, H. B., Hahne, K., Donelson, J. L., Song, J., Shrestha, L., Harrison, M. L., Hrycyna, C. A., & Gibbs, R. A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.087 · Cited by 35
A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase Inhibitors
Chen, K. X., Lesburg, C. A., Vibulbhan, B., Yang, W., Chan, T., Venkatraman, S., Velázquez, F., Zeng, Q., Bennett, F., Anilkumar, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201322r · Cited by 32
Philips, M. R. (2012) · Nature Cell Biology · doi:10.1038/ncb2429 · Cited by 26
PLCɛ and the RASSF family in tumour suppression and other functions
Chan, J. J., & Katan, M. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.07.008 · Cited by 25
Makovski, V., Haklai, R., & Kloog, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26139 · Cited by 16
Sumita, K., Yoshino, H., Sasaki, M., Majd, N., Kahoud, E. R., Takahashi, H., Takeuchi, K., Kuroda, T. S., Lee, S. D., Charest, P. G., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.531178 · Cited by 11
Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line
Li, H., Cao, H.-F., Wan, J., Li, Y., Zhu, M.-L., & Zhao, P. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i6.934 · Cited by 11
Synthetic Lethal Genetic Screens in Ras Mutant Cancers
Yu, B., & Luo, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00009-3 · Cited by 10
Self-citation
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.